An observational study in Asthma, sponsored by Singapore General Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-28.
Sponsored by Singapore General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Asthma with a site in Singapore — 3 open to participants now, 3 under way, 1 of them phase 3. Asthma · Singapore.
Among the 25 studies in Asthma with a site in Singapore, this one is the only one that started in 2011, is one of 6 observational ones, and was the 11th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →3 of the 25 studies in Asthma with a site in Singapore are open now. Recruiting first, the newest first:
Generate Biomedicines · Sites in Singapore, United States, Brazil and 18 more countries
Ages 12–80
National Healthcare Group Polyclinics · Sites in Singapore
Ages 21–65
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 21 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 253 across the 19 interventional studies, 315 across the 6 observational. Of the 18 that completed or were terminated, 3 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 25 have an industry lead sponsor. The 10 most frequent:
Singapore General Hospital is the lead sponsor of 270 studies on the registry; 57 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Singapore General Hospital has 2 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Asthma with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Asthma is a heterogenous disease. Different patients have different presentations, course of disease and response to treatment.
The investigators would like to study our population of more severe asthma and find out about their profile - demographic, clinical and inflammatory.
Asthma is a heterogeneous disorder presenting with many phenotypes. Most asthmatics have mild to moderate disease. However, 5-20% of asthmatics belong to the "Difficult-to-treat" or more severe group and they account for 50-80% of asthma health care costs. In a tertiary hospital like Singapore General Hospital, most of our asthmatics belong to the more severe group. They have more frequent healthcare visits, hospitalizations, medication use and higher risks of death.
There is currently no local data on the phenotypic profile of our patients. Asthma phenotypes which have been identified include those related to triggers ( eg. drugs such as aspirin or NSAIDS, environmental allergen, occupational allergens or irritants, exercise) or clinical physiological phenotypes ( eg. severity-defined, exacerbation-prone, chronic airflow limitation, steroid-resistant, age -of -onset) or inflammatory phenotypes ( eg. eosinophilic, neutrophilic, pauci granulocytic, mixed). With better understanding of their phenotypes, treatment can then be individually tailored to improve their asthma control and reduce future risks.
We aim to improve the understanding of this group of asthmatics such that better treatment approaches can be developed in the future. This is not a clinical trial. Its purpose is to gather information ranging from demographic data, medical history to responses to simple routine questions, to lung function, inflammation, allergy and blood testing results. The data are analyzed to improve our understanding of the clinical and inflammatory phenotypes ( or profiles) in this group of patients.
Respiratory or severe asthma clinic
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Annual exacerbation rates
Annual exacerbation rates
Time frame: Through study completion, an average of 1 year
Symptom control
Symptom control using Asthma Control Test
Time frame: Through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2011 (actual). Primary completion is estimated for Jan 2025, 168 months after the start.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 168 months is above that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.